Zhejiang Hisun Pharmaceutical Co.,Ltd.(600267),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

600267 Zhejiang Hisun Pharmaceutical Co.,Ltd.

Closed 11-26 15:00:00

8.36

-0.03

-0.36%

High8.50	Low8.35	Vol8.93M
Open8.39	D1 Closing8.39	Amplitude1.79%
Mkt Cap10.10B	Tradable Cap10.02B	Total Shares1.21B
T/O75.30M	T/O Rate0.75%	Tradable Shares1.20B
P/B1.22	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"600267","market":"SH","secType":"STK","nameCN":"Zhejiang Hisun Pharmaceutical Co.,Ltd.","latestPrice":8.36,"timestamp":1732604401000,"preClose":8.39,"halted":0,"volume":8931358,"delay":0,"changeRate":-0.0036,"floatShares":1198000000,"shares":1208000000,"eps":-0.0168,"marketStatus":"Closed","change":-0.03,"latestTime":"11-26 15:00:00","open":8.39,"high":8.5,"low":8.35,"amount":75296900,"amplitude":0.0179,"askPrice":8.37,"askSize":221,"bidPrice":8.36,"bidSize":503,"shortable":0,"etf":0,"ttmEps":-0.0168,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1732671000000},"marketStatusCode":5,"adr":0,"adjPreClose":8.39,"symbolType":"stock","openAndCloseTimeList":[[1732584600000,1732591800000],[1732597200000,1732604400000]],"highLimit":9.23,"lowLimit":7.55,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1207873716,"isCdr":false,"pbRate":1.22,"roa":"--","roe":"6.4%","epsLYR":-0.08,"committee":0.229087,"marketValue":10098000000,"turnoverRate":0.0075,"status":1,"floatMarketCap":10017000000},"requestUrl":"/m/hq/s/600267","defaultTab":"news","newsList":[{"id":"2483310059","title":"China Approves Hisun Pharma's Two Medications for Dogs","url":"https://stock-news.laohu8.com/highlight/detail?id=2483310059","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483310059?lang=en_us&edition=fundamental","pubTime":"2024-11-15 16:00","pubTimestamp":1731657602,"startTime":"0","endTime":"0","summary":"Chinese agriculture officials approved Zhejiang Hisun Pharmaceutical (SHA:600267) subsidiary Zhejiang Hisun Animal Health Products' two medications for dogs, according to a Friday filing with the Shan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600267","BK0188","BK0060","BK0239","BK0028"],"gpt_icon":0},{"id":"2477206803","title":"Hisun Pharma Unit Gets Regulatory Nod for Cat Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2477206803","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477206803?lang=en_us&edition=fundamental","pubTime":"2024-10-23 14:40","pubTimestamp":1729665635,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical's  unit, Yunnan Biopharmaceutical, received approval from China's Ministry of Agriculture and Rural Affairs for a cat vaccine, according to a Wednesday disclosure on the Shanghai Stock Exchange.The certificate for the triple inactivated vaccine for feline rhinotracheitis, calicivirus disease, and panleukopenia is valid until Sept. 1, 2026, the pharmaceutical company said.The company's shares rose 1% in recent trade.Price : 8.31, Change: +0.080, Percent Change: +0.97%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600267","BK0060","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2472515835","title":"Hisun Pharmaceutical's Parent Nominates Candidate for Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2472515835","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472515835?lang=en_us&edition=fundamental","pubTime":"2024-10-02 16:02","pubTimestamp":1727856127,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical's  controlling shareholder, Zhejiang Hisun Group, nominated Xiao Weihong as a candidate for the company's chairman, according to a Tuesday filing on the Shanghai Stock Exchange.Xiao is currently a director of the pharmaceutical company.The company's board of directors will conduct an election for the new chairman.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0060","BK0028","600267","BK0239"],"gpt_icon":0},{"id":"2472160513","title":"Hisun Pharmaceutical to Pay Additional Taxes Worth 18 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2472160513","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472160513?lang=en_us&edition=fundamental","pubTime":"2024-10-02 15:54","pubTimestamp":1727855694,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical  plans to pay additional taxes and late fees amounting to 18.1 million yuan after an internal inspection, according to a Tuesday filing on the Shanghai Stock Exchange.The amount included 15.5 million yuan in corporate income taxes, value-added taxes and other related taxes and 2.6 million yuan in late payment fees.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0239","BK0028","600267","BK0060"],"gpt_icon":0},{"id":"2470085037","title":"China Approves Hisun Pharmaceutical's Aspergillosis Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2470085037","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470085037?lang=en_us&edition=fundamental","pubTime":"2024-09-27 18:10","pubTimestamp":1727431838,"startTime":"0","endTime":"0","summary":"China's medical products administrator granted Zhejiang Hisun Pharmaceutical  drug registration approval for its posaconazole enteric-coated tablets for invasive aspergillosis in adult patients, according to a Friday filing with the Shanghai Stock Exchange.The drug is indicated for patients 13 years old and above with a higher risk for invasive aspergillus and candida infections who have low immunity due to graft-versus-host disease after stem cell transplants or low white blood cell count following chemotherapy, the filing said.Shares closed 4% during Friday's afternoon trading.Price : 7.94, Change: +0.31, Percent Change: +4.06%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK0028","BK0188","BK0060","600267"],"gpt_icon":0},{"id":"2457060468","title":"Hisun Pharmaceutical Gets Nod to Market Eltrombopag; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457060468","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457060468?lang=en_us&edition=fundamental","pubTime":"2024-08-06 15:07","pubTimestamp":1722928047,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical  received the marketing approval of China's National Medical Products Administration for its eltrombopag raw drug ingredient, according to the company's filing on the Shanghai Stock Exchange.The Chinese pharmaceutical company invested 11.9 million yuan into the raw drug ingredient, which is used for chronic immune  thrombocytopenia in patients who have not responded well to treatments, such as glucocorticoids and immunoglobulins, the Tuesday filing added.Shares of the company rose more than 3% in recent trade.Price : 7.90, Change: +0.24, Percent Change: +3.13%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK0060","BK0188","BK0028","600267"],"gpt_icon":0},{"id":"2457060079","title":"Hisun Pharmaceutical Gets Nod to Market Eltrombopag; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457060079","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457060079?lang=en_us&edition=fundamental","pubTime":"2024-08-06 15:07","pubTimestamp":1722928047,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK0188","BK0028","NHLD","BK0239","BK0060","600267"],"gpt_icon":0},{"id":"2453877088","title":"Hisun Pharmaceutical's Unit Gets Nod for Veterinary Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2453877088","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453877088?lang=en_us&edition=fundamental","pubTime":"2024-07-23 16:45","pubTimestamp":1721724323,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical's  unit, Zhejiang Hisun Animal Health Products, received approval from China's Ministry of Agriculture and Rural Affairs for veterinary drug cefpodoxime proxetil chewable tablets.The approval is valid until June 17, 2029, according to a Tuesday disclosure on the Shanghai Stock ExchangeThe drug is suitable for the treatment of canine skin infections.Shares of the company slipped less than 3% at the close.Price : 7.17, Change: -0.20, Percent Change: -2.71%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600267","BK0188","BK0239","BK0028","BK0060"],"gpt_icon":0},{"id":"2453088819","title":"Hisun Pharmaceutical's Unit Gets Nod for Veterinary Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2453088819","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453088819?lang=en_us&edition=fundamental","pubTime":"2024-07-23 16:45","pubTimestamp":1721724323,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["600267","BK0028","BK0239","BK0188","BK0060"],"gpt_icon":0},{"id":"2450537044","title":"Hisun Pharmaceutical's Veterinary Arm Gets Registration Certificate for Mirtazapine Ointment","url":"https://stock-news.laohu8.com/highlight/detail?id=2450537044","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2450537044?lang=en_us&edition=fundamental","pubTime":"2024-07-12 16:15","pubTimestamp":1720772126,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical's  unit, Zhejiang Hisun Animal Health Products, received approval from China's Ministry of Agriculture and Rural Affairs to register an ointment for cats for marketing, according to the company's disclosure on the Shanghai Stock Exchange.The drug, mirtazapine ointment, is suitable for cat weight loss, the Friday disclosure added.Price : 7.20, Change: +0.01, Percent Change: +0.14%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","ARM","600267","IE00BMPRXQ63.HKD","BK4141","IE00BMPRXN33.USD","BK0028","IE00BMPRXR70.SGD","BK0188","BK4585","LU0348723411.USD","BK4588","BK0239"],"gpt_icon":0},{"id":"2450370218","title":"Hisun Pharmaceutical's Veterinary Arm Gets Registration Certificate for Mirtazapine Ointment","url":"https://stock-news.laohu8.com/highlight/detail?id=2450370218","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2450370218?lang=en_us&edition=fundamental","pubTime":"2024-07-12 16:15","pubTimestamp":1720772126,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK4588","BK0060","BK0188","ARM","BK4585","LU0348723411.USD","600267","BK0028","IE00BMPRXR70.SGD","IE00BMPRXQ63.HKD","BK0239","IE00BMPRXN33.USD","BK4141"],"gpt_icon":0},{"id":"2446309834","title":"Hisun Pharmaceutical's Leukemia Drug Passes Chinese Drug Regulator's Consistency Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2446309834","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2446309834?lang=en_us&edition=fundamental","pubTime":"2024-06-27 15:01","pubTimestamp":1719471668,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical's  idarubicin hydrochloride passed the generic drug consistency evaluation of China's National Medical Products Administration, according to the company's disclosure on the Shanghai Stock Exchange.The pharmaceutical company filed a supplementary application for the evaluation of the drug's quality and efficacy.The drug is used for the induction of remission of untreated adult acute non-lymphocytic leukemia and it is also a second-line treatment for acute lymphocytic leukemia, the Thursday disclosure added.Shares of the company dropped more than 2% in recent trade.Price : 7.04, Change: -0.17, Percent Change: -2.36%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK0028","BK0188","BK0060","600267"],"gpt_icon":0},{"id":"2446309380","title":"Hisun Pharmaceutical's Leukemia Drug Passes Chinese Drug Regulator's Consistency Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2446309380","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2446309380?lang=en_us&edition=fundamental","pubTime":"2024-06-27 15:01","pubTimestamp":1719471668,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["600267","NHLD","BK0060","BK0188","BK0239","BK0028"],"gpt_icon":0},{"id":"2446270306","title":"Hisun Pharmaceutical's Leukemia Drug Gets Marketing Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2446270306","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2446270306?lang=en_us&edition=fundamental","pubTime":"2024-06-27 14:57","pubTimestamp":1719471437,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical's  cytarabine for injection obtained a drug registration certificate from China's National Medical Products Administration, according to the company's disclosure on the Shanghai Stock Exchange.The certificate for the marketing of the acute non-lymphocytic leukemia drug is valid until June 17, 2029, the Thursday disclosure added.Shares of the company dropped more than 2% in recent trade.Price : 7.06, Change: -0.15, Percent Change: -2.08%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0060","BK0028","600267","BK0239"],"gpt_icon":0},{"id":"2444106884","title":"Hisun Pharmaceutical Unit's Cladribine Injection Passes Regulatory Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2444106884","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2444106884?lang=en_us&edition=fundamental","pubTime":"2024-06-19 13:44","pubTimestamp":1718775877,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK0060","NHLD","600267","BK0239","BK0188","BK0028"],"gpt_icon":0},{"id":"2444103544","title":"Hisun Pharmaceutical Unit's Cladribine Injection Passes Regulatory Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2444103544","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2444103544?lang=en_us&edition=fundamental","pubTime":"2024-06-19 13:44","pubTimestamp":1718775877,"startTime":"0","endTime":"0","summary":"The drug cladribine injection, developed by Zhejiang Hisun Pharmaceutical  unit Hanhui Pharmaceutical, passed the consistency evaluation of China's National Medical Products Administration, the company said in a Wednesday filing on the Shanghai Stock Exchange. The drug, tested on whether its quality and efficiency were consistent, is used as a treatment for leukemia, according to the Wednesday filing.Shares of the company fell more than 1% in recent trade.Price : 7.40, Change: -0.10, Percent Change: -1.33%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600267","BK0188","BK0060","BK0239","BK0028"],"gpt_icon":0},{"id":"2440477860","title":"Hisun Pharmaceutical's Veterinary Arm Gets Nod to Produce Fenbendazole Oral Suspension","url":"https://stock-news.laohu8.com/highlight/detail?id=2440477860","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2440477860?lang=en_us&edition=fundamental","pubTime":"2024-06-04 14:55","pubTimestamp":1717484150,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical's  unit, Zhejiang Hisun Animal Health Products, received a veterinary drug registration certificate for fenbendazole oral suspension from China's Ministry of Agriculture and Rural Affairs, according to a Tuesday filing on the Shanghai Stock Exchange. The drug is intended to treat animals with worms such as, ascaris suum, oesophagostomum nematodes and Whipworms, the Tuesday disclosure added.Price : 7.63, Change: +0.05, Percent Change: +0.66%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0239","BK4141","BK0028","BK4588","ARM","BK4585","600267","BK0060"],"gpt_icon":0},{"id":"2440247786","title":"Hisun Pharmaceutical's Veterinary Arm Gets Nod to Produce Fenbendazole Oral Suspension","url":"https://stock-news.laohu8.com/highlight/detail?id=2440247786","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2440247786?lang=en_us&edition=fundamental","pubTime":"2024-06-04 14:55","pubTimestamp":1717484150,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK0188","BK0239","BK4141","BK0028","BK4588","ARM","BK4585","600267","BK0060"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-07-25","address":"浙江省台州市椒江区外沙路46号","stockEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":-0.0129},{"period":"3month","weight":0.1323},{"period":"6month","weight":0.084},{"period":"1year","weight":-0.1964},{"period":"ytd","weight":-0.1036}],"companyName":"浙江海正药业股份有限公司","boardCode":"AI0027","perCapita":"21275股","boardName":"医药制造业","registeredCapital":"120787万元","compareEarnings":[{"period":"1week","weight":-0.0181},{"period":"1month","weight":-0.0109},{"period":"3month","weight":0.1457},{"period":"6month","weight":0.0491},{"period":"1year","weight":0.0733},{"period":"ytd","weight":0.0971}],"survey":"　　浙江海正药业股份有限公司主营化学原料药和制剂的研发、生产和销售业务，公司的主要产品及服务是医药制剂-自营业务、医药制剂-渠道及创新业务等。公司专注于化学药,生物药,动物药,中药及商业流通等多产业发展，加快布局大健康产业和健康美学等新兴市场，多次入选中国制造业企业500强,中国医药工业百强企业榜单，先后荣获国家技术创新示范企业,全国五一劳动奖状,浙江省政府质量奖等荣誉称号。此外，报告期内公司还获得“2023年度中国化药企业TOP100”,“浙江省知产保护警企合作基地”,“浙江出口名牌”等荣誉。","serverTime":1732631018858,"listedPrice":11.83,"stockholders":"56319人(较上一季度减少3.58%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Zhejiang Hisun Pharmaceutical Co.,Ltd.(600267),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Zhejiang Hisun Pharmaceutical Co.,Ltd.(600267) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Zhejiang Hisun Pharmaceutical Co.,Ltd.,600267,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票老虎,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票老虎国际,Zhejiang Hisun Pharmaceutical Co.,Ltd.行情,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票行情,Zhejiang Hisun Pharmaceutical Co.,Ltd.股价,Zhejiang Hisun Pharmaceutical Co.,Ltd.股市,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票价格,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票交易,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票购买,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Zhejiang Hisun Pharmaceutical Co.,Ltd.(600267),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Zhejiang Hisun Pharmaceutical Co.,Ltd.(600267) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}